LFB-SA
18.4.2016 15:39:14 CEST | Business Wire | Press release
Key events in 2015 :
- Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
- Two new products registered in Europe
- Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
- Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
- Turnover of €502.4 million, stable in comparison to 2014
Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In
2015, the key milestones have been successfully achieved. It has been a
historic and productive year for the future of LFB."
An unprecedented increase in capital in order to finance the group's
development
As part of the group's strategic development, LFB's
shareholder (the French State) decided in October to underwrite an
increase in LFB's share capital by €230 million. The share capital of
the company now stands at €280 million. To meet the financing needs of
LFB's development project, on 5 January 2016 LFB issued a senior bond of
€124 million. These funds will enable the construction of a 'new
generation' plant in Arras. This flagship project, representing an
investment of approximately €300 million, will enable LFB to triple its
global production capacity in 2020 with facilities aimed at
manufacturing for the whole world.
LFB is also developing its sites
in Alès (Gard) and Charlton (USA), establishing bio-production
facilities for recombinant medicines in development.
|
Consolidated earnings in €M |
2015 | 2014 | Variation 2015/2014 | |||
|
Turnover |
502.4 |
501.9 |
0.1 % |
|||
|
Gross margin |
177.6 |
195.5 |
-9.2 % |
|||
|
Research & development |
(81.3) |
(65.9) |
||||
|
Commercial costs |
(51.0) |
(48.6) |
||||
|
General costs |
(50.3) |
(48.7) |
||||
|
Other charges and |
17.0 |
(7.1) |
||||
|
Operational earnings |
12.0 |
25.2 |
||||
|
as a % of turnover |
2.4 % |
5.0 % |
||||
|
Net earnings |
0.3 |
13 |
€90.5 million* before research tax credit
2015 turnover - growth in international sales
At €502.4
million, turnover is relatively stable as compared to 2014. For the
second successive year, the group's turnover exceeded €500 million, with
the international side business continuing to grow. Despite a 3.2 %
decline in turnover in France during 2015, international sales rose by
€12.1 million (+8.7%), reaching €152 million. This figure represents 30%
of consolidated turnover (28% in 2014).
Operational earnings decline in order to finance strategy
Research
and development costs are increasing rapidly (€81.3 million), owing to
the large number of phase III trials in progress. Various strategic
projects reached significant milestones. In 2015, two new LFB products,
a 10% immunoglobulin and a fibrinogen have been subject to a mutual
recognition in procedure in Europe with the Paul Ehrlich Institute as
the referral agency. Two other recombinant products are currently at the
end of phase III. At the same time, LFB is planning to manufacture
product batches for launch, which has had an impact on earnings. In
2015, the group posted encouraging operational income (€17 million),
notably owing to its holding in the bio-tech company TG Therapeutics
Inc. The positive operational earnings (€12.0 million) is down as
compared to that of 2014 (-13.2 million) due to a decline in gross
margins and increased development costs. Despite this unprecedented
effort, net earnings remain positive at €0.3 million.
About LFB Group
LFB is a
bio-pharmaceutical company that develops, manufactures, and markets
medicinal products from living systems for the treatment of serious and
often rare diseases in the fields of Immunology, Hemostasis, Perinatal,
and Intensive Care. Currently ranked 6th worldwide in the field of
plasma-derived medicinal products, LFB Group is also among the leading
European companies in the development and production of proteins and
innovative treatments derived from bio-technologies. It employs 2,111
staff worldwide.
http://www.groupe-lfb.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005971/en/
Contact:
LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication
Director
charrieres@lfb.fr
or
David
Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas
Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom